Literature DB >> 19857585

Therapy-related myelodysplastic syndrome: models and genetics.

Timothy Graubert1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19857585      PMCID： PMC2832708          DOI： 10.1016/j.bbmt.2009.10.019

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  29 in total

1.  Poor metabolizer status at the cytochrome P450 2C9 and 2D6 loci does not modulate susceptibility to therapy-related acute myeloid leukaemia.

Authors:  Philippa L Roddam; James M Allan; Sara Rollinson; Alexandra G Smith; Eleanor V Willett; David Swirsky; Eve Roman; Gareth J Morgan
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

2.  Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia.

Authors:  R P Witherspoon; H J Deeg; B Storer; C Anasetti; R Storb; F R Appelbaum
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

3.  Leukemia following Hodgkin's disease.

Authors:  J M Kaldor; N E Day; E A Clarke; F E Van Leeuwen; M Henry-Amar; M V Fiorentino; J Bell; D Pedersen; P Band; D Assouline
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

4.  Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.

Authors:  J M Allan; C P Wild; S Rollinson; E V Willett; A V Moorman; G J Dovey; P L Roddam; E Roman; R A Cartwright; G J Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

5.  Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.

Authors:  Jeffrey A Knight; Andrew D Skol; Abhijit Shinde; Darcie Hastings; Richard A Walgren; Jin Shao; Thelma R Tennant; Mekhala Banerjee; James M Allan; Michelle M Le Beau; Richard A Larson; Timothy A Graubert; Nancy J Cox; Kenan Onel
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

6.  An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents.

Authors:  Lisa J Worrillow; Lois B Travis; Alexandra G Smith; Sara Rollinson; Andrew J Smith; Christopher P Wild; Eric J Holowaty; Betsy A Kohler; Tom Wiklund; Eero Pukkala; Eve Roman; Gareth J Morgan; James M Allan
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

7.  RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.

Authors:  Lucy E Side; Nicole P Curtiss; Kathryn Teel; Christian Kratz; Pauline W Wang; Richard A Larson; Michelle M Le Beau; Kevin M Shannon
Journal:  Genes Chromosomes Cancer       Date:  2004-03       Impact factor: 5.006

8.  Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.

Authors:  J Pedersen-Bjergaard; L Specht; S O Larsen; J Ersbøll; J Struck; M M Hansen; H H Hansen; N I Nissen
Journal:  Lancet       Date:  1987-07-11       Impact factor: 79.321

9.  The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia.

Authors:  Claire Seedhouse; Rowena Bainton; Michael Lewis; Alexander Harding; Nigel Russell; Emma Das-Gupta
Journal:  Blood       Date:  2002-07-18       Impact factor: 22.113

10.  Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.

Authors:  C Schoch; W Kern; S Schnittger; W Hiddemann; T Haferlach
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528
View more
  5 in total

1.  Myelodysplastic syndromes--many new drugs, little therapeutic progress.

Authors:  Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2010-09-22       Impact factor: 7.616

2.  Myelodysplastic Syndrome in Patients with Gastro-Pancreatic Malignancies: A Case Series and Review of Literature.

Authors:  Amandeep Godara; Anupama Kumar; Kenneth B Miller; Muhammad Wasif Saif
Journal:  Cancer Med J       Date:  2020-06-11

3.  Radiotherapy- and chemotherapy-induced myelodysplasia syndrome: a nationwide population-based nested case-control study.

Authors:  Li-Min Sun; Cheng-Li Lin; Ming-Chia Lin; Ji-An Liang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

4.  Secondary myelodysplastic syndromes identified via next-generation sequencing in a non-small cell lung cancer patient.

Authors:  Yongzhi Feng; Xialin Chen; Keran Jiang; Ding Zhang; Feng Tao; Dan Ni; Jun Zhang; Lixin Wu; Jinping Cai; Libin Jiang; GenHua Yu; Lin Shi
Journal:  BMC Med Genomics       Date:  2021-12-20       Impact factor: 3.063

5.  Hereditary cancer syndrome-associated pathogenic variants are common in patients with hematologic malignancies subsequent to primary solid cancer.

Authors:  Joowon Oh; Yu Ri Kim; Yoonjung Kim; Boyeon Kim; Kyung Sun Park; Seong-Hyeuk Nam; Kyung-A Lee
Journal:  J Cancer       Date:  2021-05-19       Impact factor: 4.207
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.